Updates are available Correction dated 2026-05-05
Click to view Correction: https://doi.org/10.1038/s41591-026-04425-3
-
Authors
Ogbogu, Princess U.
Roufosse, Florence
Akuthota, Praveen
Kuna, Piotr https://orcid.org/0000-0003-2401-0070
Groh, Matthieu
Reiter, Andreas
Yokota, Akira
Siddiqui, Salman H.
Mutsaers, Pim G. N. J.
Li, Bing
Khoury, Paneez
Bahadori, Lila M.
Bednarczyk, Artur
Bouma, Gerben https://orcid.org/0000-0002-1465-9178
Brooks, Laura G.
Ferreira, Jorge
Grindebacke, Hanna
Ho, Calvin N. https://orcid.org/0000-0002-3360-9651
Jain, Priya
Palmer, Rebecca L.
Jison, Maria L.
Klion, Amy D. https://orcid.org/0000-0002-4986-5326
,
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | National Institutes of Health (1ZIAAI001130)
AstraZeneca
- License Information
-
More Information
Article History
Received: 24 October 2025
Accepted: 2 March 2026
First Online: 31 March 2026
Change Date: 5 May 2026
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41591-026-04425-3
Competing interests
: P.U.O. has received grant funding from AstraZeneca, Blueprint, DBV Technologies and GSK, as well as consulting fees from AstraZeneca, Novartis and BioCryst. F.R. has received consulting fees from GSK, AstraZeneca and Merck; honoraria from AstraZeneca and GSK; and royalties from UpToDate. P.A. has received grant funding from AstraZeneca, Sanofi and Recode, as well as consulting fees from AstraZeneca, Connect Biopharma, Sanofi, Regeneron, GSK, Amgen, Vida Ventures and Enveda. P. Kuna has received honoraria from Adamed, Angellini, AstraZeneca, Berlin Chemie Menarini, Glenmark, Chiesi, GSK, Celon Pharma, Polpharma, Sanofi and Teva. M.G. has received consulting fees from AstraZeneca and GSK. A.R. has received grant funding from Abbvie, AOP, AstraZeneca, BMS, Blueprint Medicines, GSK and Incyte; consulting fees from Abbvie, AOP, AstraZeneca, BMS, Blueprint Medicines, GSK, Incyte and Novartis; and honoraria from AOP, AstraZeneca, BMS, Blueprint Medicines, GSK and Novartis. S.H.S. has received consulting fees from AstraZeneca, GSK, Areteia Therapeutics, Sanofi and Chiesi; honoraria from AstraZeneca, GSK, Chiesi and Medscape; and has a patent in breath analysis and biomarkers submitted at the time of writing. P.G.N.J.M. has received grant funding from AstraZeneca. L.M.B. is employed by AstraZeneca and may hold stock in AstraZeneca. A.B. is employed by AstraZeneca and holds stock in AstraZeneca, Pfizer and GSK. G.B. is employed by AstraZeneca and may hold stock in AstraZeneca. L.G.B. is employed by AstraZeneca and may hold stock in AstraZeneca. J.F. is employed by AstraZeneca and may hold stock in AstraZeneca. H.G. is employed by AstraZeneca and may hold stock in AstraZeneca. C.N.H. is employed by AstraZeneca and may hold stock in AstraZeneca. P.J. is employed by AstraZeneca and may hold stock in AstraZeneca. R.L.P. is employed by AstraZeneca and may hold stock in AstraZeneca. M.L.J. is employed by AstraZeneca and may hold stock in AstraZeneca. A.D.K. has received royalties from UpToDate. The other authors declare no competing interests.
